Position in ABBV
as of Jun 30, 2026
· filed Jul 29, 2026
Position Value
$798,202
+$309,285 QoQ
Shares Held
3,172
+41.1% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.53%
of 13F equity value
Holder Rank
#2,756
of 4,153 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ABBV Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026REXFORD CAPITAL INC holds $12,408,269 across 14 Drug Manufacturers - General names. ABBV ranks #7 (6.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
1,675 | $2,009,045 | |
| 2 | AMGN |
Amgen Inc
|
5,498 | $1,990,935 | |
| 3 | JNJ |
Johnson & Johnson
|
6,254 | $1,588,328 | |
| 4 | AZN |
Astrazeneca PLC
|
6,735 | $1,277,090 | |
| 5 | MRK |
Merck & Co., Inc.
|
7,926 | $1,018,491 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
6,492 | $820,199 | |
| 7 | ABBV |
AbbVie Inc.
This page
|
3,172 | $798,202 | |
| 8 | NVS |
Novartis AG
|
5,059 | $792,846 |
All Filings in ABBV
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $798,202 | 3,172 | Shares | Sole | 2026-07-29 | |
| 2026-03-31 | $488,917 | 2,248 | Shares | Sole | 2026-04-24 | |
| 2025-12-31 | $506,105 | 2,215 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $512,861 | 2,215 | Shares | Sole | 2025-10-21 | |
| 2025-06-30 | $411,148 | 2,215 | Shares | Sole | 2025-08-18 | |
| No filing history on record for this holder in this stock. | ||||||